These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29980907)

  • 1. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.
    Armer JM; Ballman KV; McCall L; Armer NC; Sun Y; Udmuangpia T; Hunt KK; Mittendorf EA; Byrd DR; Julian TB; Boughey JC
    Support Care Cancer; 2019 Feb; 27(2):495-503. PubMed ID: 29980907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.
    Armer JM; Ballman KV; McCall L; Ostby PL; Zagar E; Kuerer HM; Hunt KK; Boughey JC
    JAMA Surg; 2019 Sep; 154(9):800-809. PubMed ID: 31314062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
    Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.
    Specht MC; Miller CL; Skolny MN; Jammallo LS; O'Toole J; Horick N; Isakoff SJ; Smith BL; Taghian AG
    Ann Surg Oncol; 2013 Sep; 20(9):2835-41. PubMed ID: 23689935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study.
    Zou L; Liu FH; Shen PP; Hu Y; Liu XQ; Xu YY; Pen QL; Wang B; Zhu YQ; Tian Y
    Breast Cancer; 2018 May; 25(3):309-314. PubMed ID: 29397555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of ACOSOG Z1071: Effect of Results on Patient Care and Surgical Decision-Making.
    Palmer JAV; Flippo-Morton T; Walsh KK; Gusic LH; Sarantou T; Robinson MM; White RL
    Clin Breast Cancer; 2018 Aug; 18(4):270-275. PubMed ID: 29129549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphedema following axillary lymph node dissection for breast cancer.
    Sakorafas GH; Peros G; Cataliotti L; Vlastos G
    Surg Oncol; 2006 Nov; 15(3):153-65. PubMed ID: 17187979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Boughey JC; Ballman KV; Hunt KK; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Le-Petross HT
    J Clin Oncol; 2015 Oct; 33(30):3386-93. PubMed ID: 25646192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton TS; Kuerer HM; Bowling M; Hunt KK;
    Ann Surg; 2015 Mar; 261(3):547-52. PubMed ID: 25664534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?
    Specht MC; Miller CL; Russell TA; Horick N; Skolny MN; O'Toole JA; Jammallo LS; Niemierko A; Sadek BT; Shenouda MN; Finkelstein DM; Smith BL; Taghian AG
    Breast Cancer Res Treat; 2013 Aug; 140(3):485-94. PubMed ID: 23912961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.
    Helyer LK; Varnic M; Le LW; Leong W; McCready D
    Breast J; 2010; 16(1):48-54. PubMed ID: 19889169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up.
    Ribeiro Pereira ACP; Koifman RJ; Bergmann A
    Breast; 2017 Dec; 36():67-73. PubMed ID: 28992556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative axillary surgery in breast cancer patients undergoing mastectomy: long-term results.
    Cowher MS; Grobmyer SR; Lyons J; O'Rourke C; Baynes D; Crowe JP
    J Am Coll Surg; 2014 Apr; 218(4):819-24. PubMed ID: 24655877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De Novo Upper Extremity Lymphedema After Elective Hand Surgery in Breast Cancer Survivors.
    Baltzer HL; Harvey J; Fox PM; Moran SL
    Ann Plast Surg; 2017 Jul; 79(1):24-27. PubMed ID: 28187025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the quality of life in breast cancer survivors at risk for lymphedema.
    Bland KL; Kosir MA
    Surgery; 2019 Oct; 166(4):686-690. PubMed ID: 31474490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.
    Armer JM; Stewart BR
    Lymphology; 2010 Sep; 43(3):118-27. PubMed ID: 21226414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Le-Petross HT; McCall LM; Hunt KK; Mittendorf EA; Ahrendt GM; Wilke LG; Ballman KV; Boughey JC
    AJR Am J Roentgenol; 2018 Mar; 210(3):669-676. PubMed ID: 29381381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.
    McLaughlin SA; Wright MJ; Morris KT; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
    J Clin Oncol; 2008 Nov; 26(32):5220-6. PubMed ID: 18838708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological safety of selective axillary dissection after axillary reverse mapping in node-positive breast cancer.
    Gennaro M; Listorti C; Mariani L; Maccauro M; Bianchi G; Capri G; Maugeri I; Lozza L; De Santis MC; Folli S
    Eur J Surg Oncol; 2021 Jul; 47(7):1606-1610. PubMed ID: 33160781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.